• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

lay offs

  1. Medela lays off all in wound division

    Entire department cut down to basically a few remote hybrid reps. With some feet on the street “business managers”, former regional managers who were demoted, to visit prospects and handle proposals. Everything will be outsourced to 1099’s from there.
  2. Medela Wound Reps all let go

    Entire department cut down to basically a few remote hybrid reps. With some feet on the street “business managers”, former regional managers who were demoted, to visit prospects and handle proposals. Everything will be outsourced to 1099’s from there.
  3. GSK 2019 is a mess

    Pharma field and those associated with it is a complete mess..... - Ride alongs have become performance theater that are less business focused each year. - Ratings are a scripted show with calibrations being the writers room script of what’s to come. -Generic Advair is gonna wreck ish. -...
  4. Latuda Cliff & Bad Resp Sales = lay offs

    Hope you are ready folks because lay offs are happening in Spring 2018. There is nothing in the pipeline to save us this time. All of the resp products are costing money, not making money. Meetings are taking place already and the talks are that 40% of field and corporate will be gone by...